• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Schrodinger Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    6/18/25 4:09:48 PM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SDGR alert in real time by email
    sdgr-20250618
    1540 Broadway24th FloorNew YorkNYFALSE000149097800014909782025-06-182025-06-18

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549
    ________________________________________
    FORM 8-K
    ________________________________________
    CURRENT REPORT
    Pursuant to Section 13 or 15(d)
    of the Securities Exchange Act of 1934
    Date of Report (Date of earliest event reported): June 18, 2025
    ________________________________________
    Schrodinger, Inc.
    (Exact name of Registrant as Specified in Its Charter)
    ________________________________________
    Delaware001-3920695-4284541
    (State or other jurisdiction of
    incorporation or organization)
    (I.R.S. Employer
    Identification No.)
    (Commission File Number)
    1540 Broadway, 24th Floor
    New York, NY
    10036
    (Address of principal executive offices)(Zip Code)
    Registrant’s telephone number, including area code: (212) 295-5800
    Not Applicable
    (Former Name or Former Address, if Changed Since Last Report)
    ________________________________________
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
    oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
    Securities registered pursuant to Section 12(b) of the Act:
    Title of each classTrading
    Symbol(s)
    Name of each exchange on which registered
    Common stock, par value $0.01 per shareSDGRThe Nasdaq Stock Market LLC
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
    Emerging growth company o
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

    Item 5.07 Submission of Matters to a Vote of Security Holders.
    At the 2025 Annual Meeting of Stockholders of Schrödinger, Inc. (the “Company”), held on June 18, 2025 (the “Annual Meeting”), the Company’s stockholders voted on the three proposals set forth below. A more detailed description of each proposal is set forth in the Company’s Proxy Statement for the Annual Meeting filed with the Securities and Exchange Commission on April 24, 2025.
    Holders of the Company’s common stock were entitled to one vote per share of common stock on each matter brought before the Annual Meeting. Holders of the Company’s limited common stock were entitled to one vote per share of limited common stock on each matter brought before the Annual Meeting, except that each share of limited common stock was not entitled to vote on the election of directors.
    Proposal 1 – Election of Four Class II Directors
    The Company’s stockholders elected Jeffrey Chodakewitz, Michael Lynton, Nancy A. Thornberry, and Bridget van Kralingen as Class II directors of the board of directors, each to serve for a three-year term expiring at the 2028 Annual Meeting of Stockholders and until his or her respective successor is duly elected and qualified. The results of the stockholders’ vote with respect to the election of such Class II directors were as follows:
    Nominee
    Number of Shares of Common Stock FOR
    Number of Shares of Common Stock AGAINST
    Number of Shares of Common Stock ABSTAINING
    BROKER NON-VOTES
    Jeffrey Chodakewitz
    44,010,885633,12427,1157,885,651
    Michael Lynton
    32,354,60512,288,93827,5817,885,651
    Nancy A. Thornberry
    44,012,696612,24746,1817,885,651
    Bridget van Kralingen
    44,203,761440,68426,6797,885,651

    Proposal 2 – Advisory Vote on Executive Compensation
    The Company’s stockholders approved the non-binding, advisory vote on the compensation paid to its named executive officers. The results of the stockholders’ non-binding, advisory vote with respect to compensation paid to the Company’s named executive officers were as follows:
    Number of Shares FOR
    Number of Shares AGAINST
    Number of Shares ABSTAINING
    BROKER NON-VOTES
    Common Stock
    41,593,9583,028,65048,5167,885,651
    Limited Common Stock
    9,164,193000
    Total
    50,758,1513,028,65048,5167,885,651


    Proposal 3 – Ratification of the Appointment of KPMG LLP as the Company’s Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2025
    The Company’s stockholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025. The results of the stockholders’ vote with respect to such ratification were as follows:



    Number of Shares FOR
    Number of Shares AGAINST
    Number of Shares ABSTAINING
    Common Stock
    52,190,272335,20331,300
    Limited Common Stock
    9,164,19300
    Total
    61,354,465335,20331,300





    SIGNATURES
    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
    Schrödinger, Inc.
    Date: June 18, 2025
    By:/s/ Yvonne Tran
    Yvonne Tran
    Executive Vice President and Chief Legal Officer








    Get the next $SDGR alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $SDGR

    DatePrice TargetRatingAnalyst
    7/3/2025$28.00Equal-Weight
    Morgan Stanley
    7/2/2024$29.00Outperform
    Leerink Partners
    12/5/2023$38.00Overweight
    KeyBanc Capital Markets
    5/5/2023$60.00Overweight
    Piper Sandler
    12/19/2022$23.00Neutral
    Goldman
    3/1/2022$55.00Buy
    Citigroup
    11/19/2021$82.00 → $49.00Overweight → Equal-Weight
    Morgan Stanley
    11/19/2021$87.00Overweight
    Piper Sandler
    More analyst ratings

    $SDGR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Chodakewitz Jeffrey was granted 5,997 shares, increasing direct ownership by 53% to 17,247 units (SEC Form 4)

      4 - Schrodinger, Inc. (0001490978) (Issuer)

      6/20/25 4:37:45 PM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Sender Gary was granted 5,997 shares, increasing direct ownership by 53% to 17,247 units (SEC Form 4)

      4 - Schrodinger, Inc. (0001490978) (Issuer)

      6/20/25 4:36:31 PM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Lynton Michael was granted 5,997 shares, increasing direct ownership by 53% to 17,247 units (SEC Form 4)

      4 - Schrodinger, Inc. (0001490978) (Issuer)

      6/20/25 4:35:05 PM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SDGR
    SEC Filings

    See more
    • Schrodinger Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Schrodinger, Inc. (0001490978) (Filer)

      6/18/25 4:09:48 PM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Schrodinger Inc.

      8-K - Schrodinger, Inc. (0001490978) (Filer)

      5/20/25 6:44:43 AM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Schrodinger Inc.

      8-K - Schrodinger, Inc. (0001490978) (Filer)

      5/19/25 4:16:35 PM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SDGR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

      Schrödinger, Inc. (NASDAQ:SDGR) today reported that on July 14, 2025, the company granted restricted stock units (RSUs) with respect to 3,488 shares of the company's common stock to three newly hired employees. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company's board of directors, and were made as a material inducement to such employees' acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of his or her employment compensation. The RSUs vest over four years, with 25 percent of such RSUs ve

      7/18/25 8:00:00 AM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ajax Therapeutics and Schrödinger Expand Research Collaboration to Include Additional JAK Target

      Ajax Therapeutics, Inc. and Schrödinger, Inc. (NASDAQ:SDGR) today announced an expansion of their exclusive research collaboration to include a new Janus kinase (JAK) target. The partnership was established in 2019 with a goal of leveraging Schrödinger's advanced computational platform and Ajax's structural biology insights to develop a pipeline of novel molecules, with a focus on JAK inhibitors. Ajax's lead candidate from the collaboration, AJ1-11095, is a potential first-in-class Type II JAK2 inhibitor currently being evaluated in a Phase 1 clinical study for the treatment of myelofibrosis. "We're excited to expand our longstanding research collaboration with Schrödinger," stated Martin

      7/17/25 8:00:00 AM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Schrödinger Receives Fast Track Designation for SGR-1505 for the Treatment of Relapsed/Refractory Waldenström Macroglobulinemia

      Demonstrates the potential of SGR-1505 as a novel approach for diseases with high unmet medical need Schrödinger, Inc. (NASDAQ:SDGR) today announced that SGR-1505, its clinical stage MALT1 inhibitor, was designated as a Fast Track product by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with Waldenström macroglobulinemia that have failed at least two lines of therapy, including a Bruton's tyrosine kinase (BTK) inhibitor. "We are excited to receive Fast Track designation for SGR-1505, which underscores the significant need in patients with Waldenström macroglobulinemia," said Karen Akinsanya, Ph.D., president, head of therapeutics R&D and chief strategy

      6/27/25 8:00:00 AM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SDGR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Morgan Stanley resumed coverage on Schrodinger with a new price target

      Morgan Stanley resumed coverage of Schrodinger with a rating of Equal-Weight and set a new price target of $28.00

      7/3/25 7:52:31 AM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Leerink Partners initiated coverage on Schrodinger with a new price target

      Leerink Partners initiated coverage of Schrodinger with a rating of Outperform and set a new price target of $29.00

      7/2/24 8:03:41 AM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • KeyBanc Capital Markets initiated coverage on Schrodinger with a new price target

      KeyBanc Capital Markets initiated coverage of Schrodinger with a rating of Overweight and set a new price target of $38.00

      12/5/23 8:08:54 AM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SDGR
    Leadership Updates

    Live Leadership Updates

    See more
    • Schrödinger Expands Executive Leadership Team with Appointment of Mannix Aklian as Chief Commercial Officer, Global Head of Software Sales and Marketing

      Schrödinger, Inc. (NASDAQ:SDGR) today announced the expansion of its leadership team with the appointment of Mannix Aklian as executive vice president, chief commercial officer, global head of software sales and marketing. Mr. Aklian brings more than 25 years of experience in software sales and leadership roles within the biopharmaceutical and technology industries. Mr. Aklian will have global oversight of Schrödinger's account management teams and will be responsible for the continued growth of the company's software business, including the go-to-market strategy for enhancements and new products within Schrödinger's computational platform. "Mannix joins Schrödinger at a pivotal time as w

      5/29/25 8:00:00 AM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Schrödinger Expands Board of Directors with Appointment of Bridget van Kralingen

      Schrödinger, Inc. (NASDAQ:SDGR) today announced the appointment of Bridget van Kralingen to its Board of Directors, effective March 7, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250310010062/en/Bridget van Kralingen was appointed to Schrödinger's Board of Directors in March 2025. (Photo: Business Wire) "Bridget has a proven track record of growing global software businesses, and we are pleased to welcome her to our Board," said Ramy Farid, Ph.D., chief executive officer of Schrödinger. "Bridget's leadership experience overseeing strategic initiatives at global technology companies, including IBM, will be valuable to Sch

      3/10/25 8:30:00 AM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Schrödinger Appoints Geoffrey Porges as Chief Financial Officer

      Schrödinger, Inc. (NASDAQ:SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced the appointment of Geoffrey Porges, MBBS., as chief financial officer. Dr. Porges brings to Schrödinger more than 30 years of experience in executive, advisory and investment roles within the biopharmaceutical industry. As Schrödinger's CFO, he will lead all aspects of the company's financial operations and investor relations and corporate affairs activities. He will also oversee business development and strategic planning for the company's proprietary pharmaceuticals and biopharmaceutical collaborations. This press release features multim

      8/18/22 7:01:00 AM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SDGR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Schrodinger Inc.

      SC 13G - Schrodinger, Inc. (0001490978) (Subject)

      11/13/24 4:30:25 PM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Schrodinger Inc. (Amendment)

      SC 13G/A - Schrodinger, Inc. (0001490978) (Subject)

      2/13/24 5:13:59 PM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Schrodinger Inc. (Amendment)

      SC 13G/A - Schrodinger, Inc. (0001490978) (Subject)

      1/23/24 11:52:31 AM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SDGR
    Financials

    Live finance-specific insights

    See more
    • Schrödinger Reports Encouraging Initial Phase 1 Clinical Data for SGR-1505 at EHA Annual Congress

      SGR-1505 was observed to have a favorable safety profile and was well tolerated, with encouraging preliminary efficacy in patients with relapsed/refractory B-cell malignancies Responses observed across a broad range of B-cell malignancies, including monotherapy responses in patients with CLL and Waldenström macroglobulinemia Management to host a webcast today at 8:00 a.m. ET Schrödinger, Inc. (NASDAQ:SDGR) today announced encouraging initial clinical data from its ongoing Phase 1, open-label, dose-escalation study of SGR-1505 in patients with relapsed/refractory B-cell malignancies. SGR-1505 was observed to be safe, well tolerated, and clinically active, with responses observed in mul

      6/12/25 7:00:00 AM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Schrödinger Announces CFO Appointment

      Richie Jain to succeed Geoffrey Porges as CFO Schrödinger (NASDAQ:SDGR) today announced that the company and Geoffrey Porges, MBBS., have mutually agreed that Dr. Porges will depart from his role as chief financial officer to pursue other opportunities. Richie Jain, who previously served as Schrödinger's senior vice president, strategic finance and head of corporate and business development, will succeed Geoffrey Porges as chief financial officer. Dr. Porges will serve as an advisor to the company through June 6, 2025, to ensure a smooth transition. "I want to thank Geoff for his commitment and service during his tenure. He strengthened the company's financial profile to support continued

      5/20/25 6:30:00 AM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Schrödinger to Present Phase 1 Clinical Data on MALT1 Inhibitor SGR-1505 at EHA Annual Congress and International Conference on Malignant Lymphoma

      Company to host webcast to review data on Thursday, June 12, 2025 at 8:00 a.m. ET Schrödinger, Inc. (NASDAQ:SDGR) today announced that initial Phase 1 clinical data for SGR-1505, its investigational MALT1 inhibitor, will be presented at the European Hematology Association Annual Congress, taking place June 12 - 15, 2025, in Milan, Italy. Additional data from this trial will be presented at the International Conference on Malignant Lymphoma, taking place June 17 - 21, 2025, in Lugano, Switzerland. The Phase 1 study is designed to evaluate the safety, tolerability and anti-tumor activity of SGR-1505 in patients with relapsed/refractory B-cell malignancies. The poster presentations will incl

      5/14/25 9:30:00 AM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care